Ratings by Barclays (Travis Steed)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/11/2026 | Becton Dickinson | BDX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/3/2025 | Becton Dickinson | BDX | Maintain | Overweight (N/A) |
|
Details | ||
| 4/8/2025 | Becton Dickinson | BDX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/14/2025 | Becton Dickinson | BDX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/6/2024 | Becton Dickinson | BDX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/5/2024 | Becton Dickinson | BDX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/7/2023 | Becton Dickinson | BDX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/8/2023 | Becton Dickinson | BDX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/6/2023 | Becton Dickinson | BDX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/13/2021 | InMode Ltd. | INMD | Maintain | Overweight (N/A) |
|
Details | ||
| 10/5/2021 | Zimmer Biomet | ZBH | Maintain | Overweight (N/A) |
|
Details | ||
| 9/3/2021 | Baxter International | BAX | Upgrade | Overweight (Equalweight) |
81.06 (26.34) |
-67.51% | Details | |
| 8/6/2021 | Axonics Modulation Technologies Inc. | AXNX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/13/2021 | InMode Ltd. | INMD | Maintain | Overweight (N/A) |
|
Details | ||
| 7/12/2021 | Axonics Modulation Technologies Inc. | AXNX | New Coverage | Overweight (N/A) |
62.92 (70.98) |
12.81% | Details | |
| 6/2/2021 | Abbott Labs | ABT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/25/2021 | Zimmer Biomet | ZBH | New Coverage | Overweight (N/A) |
167.32 (100.98) |
-39.65% | Details | |
| 5/25/2021 | Tandem Diabetes Care | TNDM | New Coverage | Underweight (N/A) |
85.74 (22.32) |
-73.97% | Details | |
| 5/25/2021 | Stryker | SYK | New Coverage | Underweight (N/A) |
255.65 (329.45) |
28.87% | Details | |
| 5/25/2021 | Medtronic, Inc. | MDT | New Coverage | Equalweight (N/A) |
127.29 (93.35) |
-26.66% | Details | |
| 5/25/2021 | Insulet Corporation | PODD | New Coverage | Overweight (N/A) |
253.52 (148.16) |
-41.56% | Details | |
| 5/25/2021 | InMode Ltd. | INMD | New Coverage | Overweight (N/A) |
80.05 (15.06) |
-81.19% | Details | |
| 5/25/2021 | Edwards Lifesciences | EW | New Coverage | Overweight (N/A) |
94.20 (89.79) |
-4.68% | Details | |
| 5/25/2021 | DexCom | DXCM | New Coverage | Overweight (N/A) |
342.09 (92.34) |
-73.01% | Details | |
| 5/25/2021 | CONMED | CNMD | New Coverage | Overweight (N/A) |
101.41 (51.07) |
-49.64% | Details | |
| 5/25/2021 | Cardiovascular Systems | CSII | New Coverage | Equalweight (N/A) |
38.53 (20.00) |
-48.09% | Details | |
| 5/25/2021 | Boston Scientific | BSX | New Coverage | Overweight (N/A) |
42.11 (50.37) |
19.62% | Details | |
| 5/25/2021 | Becton Dickinson | BDX | New Coverage | Equalweight (N/A) |
244.48 (207.39) |
-15.17% | Details | |
| 5/25/2021 | Baxter International | BAX | New Coverage | Equalweight (N/A) |
83.06 (26.34) |
-68.29% | Details | |
| 5/25/2021 | Abbott Labs | ABT | New Coverage | Overweight (N/A) |
117.13 (116.64) |
-0.42% | Details |
